Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [9]. Core Insights - The company reported significant growth in Q1 2025, with revenue reaching 1.746 billion yuan, a year-on-year increase of 10.15% and a quarter-on-quarter increase of 53.34%. The net profit attributable to shareholders was 156 million yuan, reflecting a year-on-year growth of 89.10% and a quarter-on-quarter growth of 194.06% [4][5]. - The increase in profit is attributed to rising sales volumes and prices of certain pesticide and chlor-alkali products, along with a decrease in costs leading to improved gross margins [5]. - The company aims to expedite the production and effectiveness of incremental projects, driving strategic transformation and high-quality development [7][8]. Financial Performance - The company’s financial metrics for Q1 2025 include a sales expense ratio of 0.98%, a management expense ratio of 5.80%, and a research and development expense ratio of 2.84% [6]. - The company has initiated 11 new R&D projects in 2024, with a total of 17 projects currently under research, and has successfully launched 6 new pesticide formulations [6]. Production Capacity and Strategic Goals - The company is one of the major domestic producers of glyphosate, with an annual production capacity of 70,000 tons, including 30,000 tons from the glycine method and 40,000 tons from the IDAN method. An additional 50,000 tons of capacity is under construction, expected to be completed by the end of 2025 [7]. - The company plans to push for the early production and effectiveness of projects in branches such as Jijiang and Guizhou, and is considering mergers and acquisitions to cultivate new core competencies [7]. Profit Forecast - The company is expected to see continued growth in net profit, with projections of 442 million yuan, 669 million yuan, and 901 million yuan for the years 2025, 2026, and 2027 respectively. The corresponding price-to-earnings ratios are forecasted to be 17.6, 11.6, and 8.6 times [9][11].
江山股份(600389):公司事件点评报告:Q1业绩同比、环比均实现增长,持续推进增量项目达产达效